Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma

被引：2
|
作者：
Fukahori, Masaru [1 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : 188 - 194
  • [32] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
  • [33] Gemcitabine in combination with oxaliplatin as second-line therapy of advanced and metastatic NSCLC
    Alencar, A. J.
    Blaya, M.
    Raez, L.
    Farfan, N.
    Lopes, G.
    Walker, G.
    Flores, A.
    Macintyre, J.
    Rocha-Lima, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Amal Rayan
    Ola N. Abdel Fattah
    Ahmed Soliman
    Hosam A. Hasan
    Asmaa M. Zahran
    Journal of Gastrointestinal Cancer, 2019, 50 : 519 - 524
  • [35] Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study
    Ryusei Matsuyama
    Daisuke Morioka
    Ryutaro Mori
    Seigo Hiratani
    Yasuhiro Yabushita
    Yohei Ota
    Takafumi Kumamoto
    Koichi Taniguchi
    Itaru Endo
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 949 - 955
  • [36] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Rayan, Amal
    Fattah, Ola N. Abdel
    Soliman, Ahmed
    Hasan, Hosam A.
    Zahran, Asmaa M.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (03) : 519 - 524
  • [37] Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis.
    Lino, Aline Da Rocha
    Martins Junior, Rodnei Merlrina
    Abrahao, Carina Mina
    Moreira, Raphael Brandao
    Soares de Sousa, Tarcia Tarciane
    Gomes, Jessica Ribeiro
    Alessandretti, Matheus Bongers
    Fernandes Amarante, Marcus Paulo
    Ferrian, Andrea Malta
    Barros Schutz, Fabio Augusto
    Kawamura, Carolina
    Schmerling, Rafael
    Cruz, Marcelo Rocha
    Peixoto, Renata D'Alpino
    Cesar Machado, Marcel Cerqueira
    Buzaid, Antonio C.
    Maluf, Fernando C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Apartinib in combination with S-1 for the second-line treatment of advanced pancreatic cancer (APC)
    Hang, Junjie
    Wu, Lixia
    Yin, Ruohan
    Liu, Muhan
    Xu, Kequn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma
    Ajouz H.
    Mukherji D.
    Haydar A.
    Yakan A.S.
    Saleh A.
    Elias E.
    Temraz S.
    Faraj W.
    Khalife M.
    Shamseddine A.
    Journal of Gastrointestinal Cancer, 2014, 45 (1) : 109 - 112
  • [40] Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer:: A multicenter phase II trial.
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stötzer, O.
    Mueller, E.
    Depenbrock, H.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
12345